menu
    • menu
    [{"orgOrder":0,"company":"Renaissance Pharma","sponsor":"Renaissance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Dinutuximab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Renaissance Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renaissance Pharma \/ Renaissance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renaissance Pharma \/ Renaissance Pharma"},{"orgOrder":0,"company":"Renaissance Pharma","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Hu14.18K322A","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Renaissance Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renaissance Pharma \/ Essential Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Renaissance Pharma \/ Essential Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Renaissance Pharma

    Menu

    Renaissance Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    • Drug Product Manufacturing

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Renaissance Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Renaissance Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hu14.18K322A

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Essential Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Essential Pharma Acquires Renaissance Pharma's Immunotherapy for High-Risk Neuroblastoma

                            Details : Through the acquisition, Essential Pharma will leverage Renaissance clinical-stage immunotherapy product Hu14.18 (Hu14.18K322A) for the treatment of high-risk neuroblastoma.

                            Brand Name : Hu14.18

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 09, 2024

                            Lead Product(s) : Hu14.18K322A

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Essential Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Renaissance Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Renaissance Pharma

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : St. Jude Children’s Research Hospital

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Renaissance Pharma Launches Today and Announces the In-Licensing of Hu14.18K322A (Hu14.18) from St. Jude Child...

                            Details : Under the agreement, Renaissance gains exclusive development, manufacturing and commercialisation rights for Hu14.18K322A, an anti GD2 humanised mAb in development by St. Jude for the treatment of newly diagnosed high-risk neuroblastoma.

                            Brand Name : Hu14.18K322A

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 01, 2023

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : St. Jude Children’s Research Hospital

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth